References

Treatment of methicillin-resistant Staphylococcus aureus (MRSA): updated guidelines from the UK

10.1093/jacamr/dlaa114 · 2021 · External reference

Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications

10.1128/cmr.00042-09 · 2010 · External reference

Reduced susceptibility and resistance to vancomycin of Staphylococcus aureus: A review of global incidence patterns and related genetic mechanisms

2021 · External reference

Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical isolates: a systematic review and meta-analysis

10.1038/s41598-020-69058-z · 2020 · External reference

Vancomycin heteroresistance (hVISA) in MRSA links to treatment failure and supports a revised PAP-AUC threshold

10.1038/s41467-025-66118-8 · 2025 · External reference

Clinical outcomes in patients with heterogeneous vancomycin-intermediate Staphylococcus aureus bloodstream infection

10.1128/aac.00380-13 · 2013 · External reference

Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years

10.1128/jcm.02135-08 · 2009 · External reference

Global distribution of heterogeneous vancomycin-intermediate Staphylococcus aureus strains (1997-2021): a systematic review and meta-analysis

10.1016/j.jgar.2024.02.002 · 2024 · External reference

Comparison of detection methods for heteroresistant vancomycin-intermediate Staphylococcus aureus, with the population analysis profile method as the reference method

10.1128/jcm.01128-10 · 2011 · External reference

10.1093/cid/ciaa303

10.1093/cid/ciaa303 · 2020 · External reference

Activity of simulated serum concentrations of daptomycin versus vancomycin during the first 24h of treatment in the presence of physiological albumin concentrations against vancomycin-susceptible, -tolerant or -intermediate-resistant Staphylococcus aureus

10.1016/j.ijantimicag.2010.12.007 · 2011 · External reference

Sequence type 5 (ST5) as a possible predictor of bacterial persistence in adult patients with methicillin-resistant Staphylococcus aureus pneumonia treated with vancomycin

10.1128/spectrum.01348-22 · 2022 · External reference

Comparative efficacy of vancomycin in treating ST5 and ST764 methicillin-resistant Staphylococcus aureus infections in adult patients

10.1128/msphere.00457-23 · 2023 · External reference

Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China

10.1128/aac.00206-09 · 2009 · External reference

Impact of vancomycin use trend change due to the availability of alternative antibiotics on the prevalence of Staphylococcus aureus with reduced vancomycin susceptibility: a 14-year retrospective study

10.1186/s13756-022-01140-9 · 2022 · External reference

Genotype-specific prevalence of heterogeneous vancomycin-intermediate Staphylococcus aureus in Asian countries

10.1016/j.ijantimicag.2015.03.009 · 2015 · External reference

Resistance and molecular characteristics of methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate Staphylococcus aureus

10.2147/idr.s392908 · 2023 · External reference

CLSI performance standards for antimicrobial susceptibility testing

2022 · External reference

A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital

10.1093/jac/47.4.399 · 2001 · External reference

Velvet: algorithms for de novo short read assembly using de Bruijn graphs

10.1101/gr.074492.107 · 2008 · External reference

High prevalence of a globally disseminated hypervirulent clone, Staphylococcus aureus CC121, with reduced vancomycin susceptibility in community settings in China

10.1093/jac/dkz232 · 2019 · External reference

Prevalence and clinical impact of heterogeneous vancomycin-intermediate Staphylococcus aureus isolated from hospitalized patients

10.3343/alm.2016.36.3.235 · 2016 · External reference

Investigation of heteroresistant vancomycin intermediate Staphylococcus aureus among MRSA isolates

10.3855/jidc.12799 · 2021 · External reference

qacA is a key factor in heteroresistance to vancomycin in sequence type 5 methicillin-resistant Staphylococcus aureus isolates from pneumonia patients

2026 · External reference

beta-Lactam combinations with vancomycin show synergistic activity against vancomycin-susceptible Staphylococcus aureus, vancomycin-intermediate S. aureus (VISA), and heterogeneous VISA

10.1128/aac.00157-18 · 2018 · External reference

Combination antibiotic exposure selectively alters the development of vancomycin intermediate resistance in Staphylococcus aureus

10.1128/aac.02100-17 · 2018 · External reference

Predominance of ST5-II-t311 clone among healthcare-associated methicillin-resistant Staphylococcus aureus isolates recovered from Zhejiang, China

10.1016/j.ijid.2018.04.798 · 2018 · External reference

Using core-genome multilocus sequence typing to monitor the changing epidemiology of methicillin-resistant Staphylococcus aureus in a teaching hospital

10.1093/cid/ciy644 · 2018 · External reference

Prevalence and WGS-based characteristics of MRSA isolates in hospitals in Shanghai

2022 · External reference

Dissemination of methicillin-resistant Staphylococcus aureus sequence type 764 isolates with mupirocin resistance in China

10.1128/spectrum.03794-22 · 2023 · External reference

Trends in the minimum inhibitory concentrations for four agents against methicillin-resistant Staphylococcus aureus in bloodstream infections in China: a 6-year multi-center study from 2017 to 2022

10.1016/j.dcit.2025.100052 · 2025 · External reference